<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>PRECISE-HBR Documentation - Clinical Evidence & Implementation Guide</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            line-height: 1.6;
            color: #333;
            background: #f8f9fa;
        }
        
        .container {
            max-width: 1000px;
            margin: 0 auto;
            padding: 20px;
        }
        
        .header {
            background: white;
            border-radius: 10px;
            padding: 40px;
            margin-bottom: 30px;
            box-shadow: 0 2px 10px rgba(0,0,0,0.1);
            text-align: center;
        }
        
        .nav {
            background: white;
            border-radius: 10px;
            padding: 20px;
            margin-bottom: 30px;
            box-shadow: 0 2px 10px rgba(0,0,0,0.1);
            text-align: center;
        }
        
        .nav a {
            display: inline-block;
            padding: 10px 20px;
            margin: 5px;
            background: #dc3545;
            color: white;
            text-decoration: none;
            border-radius: 5px;
            transition: background-color 0.3s;
        }
        
        .nav a:hover {
            background: #c82333;
        }
        
        .section {
            background: white;
            border-radius: 10px;
            padding: 30px;
            margin-bottom: 30px;
            box-shadow: 0 2px 10px rgba(0,0,0,0.1);
        }
        
        h1 {
            color: #dc3545;
            font-size: 2.5em;
            margin-bottom: 20px;
            text-align: center;
        }
        
        h2 {
            color: #dc3545;
            font-size: 1.8em;
            margin-bottom: 15px;
            border-bottom: 2px solid #dc3545;
            padding-bottom: 5px;
        }
        
        h3 {
            color: #495057;
            font-size: 1.3em;
            margin-bottom: 10px;
            margin-top: 20px;
        }
        
        .highlight-box {
            background: #fff3cd;
            border: 1px solid #ffeaa7;
            border-radius: 5px;
            padding: 15px;
            margin: 20px 0;
        }
        
        .alert {
            background: #f8d7da;
            border: 1px solid #f5c6cb;
            border-radius: 5px;
            padding: 15px;
            margin: 20px 0;
        }
        
        .alert-warning {
            background: #fff3cd;
            border: 1px solid #ffeaa7;
        }
        
        .alert-info {
            background: #d1ecf1;
            border: 1px solid #bee5eb;
        }
        
        .code-block {
            background: #f8f9fa;
            border: 1px solid #dee2e6;
            border-radius: 5px;
            padding: 15px;
            font-family: 'Courier New', monospace;
            margin: 15px 0;
            overflow-x: auto;
        }
        
        .score-table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
        }
        
        .score-table th,
        .score-table td {
            border: 1px solid #dee2e6;
            padding: 12px;
            text-align: left;
        }
        
        .score-table th {
            background: #dc3545;
            color: white;
            font-weight: bold;
        }
        
        .score-table tr:nth-child(even) {
            background: #f8f9fa;
        }
        
        .risk-categories {
            display: flex;
            gap: 20px;
            margin: 20px 0;
            flex-wrap: wrap;
        }
        
        .risk-category {
            flex: 1;
            min-width: 250px;
            padding: 20px;
            border-radius: 10px;
            text-align: center;
            color: white;
        }
        
        .low-risk {
            background: #28a745;
        }
        
        .moderate-risk {
            background: #ffc107;
            color: #212529;
        }
        
        .high-risk {
            background: #dc3545;
        }
        
        .evidence-box {
            background: #e7f3ff;
            border-left: 4px solid #007bff;
            padding: 20px;
            margin: 20px 0;
        }
        
        .citation {
            font-style: italic;
            color: #666;
            font-size: 0.9em;
            margin-top: 10px;
        }
        
        ul {
            margin: 15px 0;
            padding-left: 30px;
        }
        
        li {
            margin: 5px 0;
        }
        
        .footer {
            text-align: center;
            padding: 20px;
            color: #666;
            font-size: 0.9em;
        }
    </style>
</head>
<body>
    <div class="container">
        <!-- Header -->
        <div class="header">
            <h1>ü©∏ PRECISE-HBR Documentation</h1>
            <p style="font-size: 1.2em; color: #666; margin-top: 10px;">
                Predicting bleeding complications in patients undergoing stent implantation and subsequent Dual AntiPlatelet Therapy
            </p>
            <p style="margin-top: 15px; color: #dc3545; font-weight: bold;">
                Clinical Evidence-Based Bleeding Risk Assessment Tool
            </p>
        </div>

        <!-- Navigation -->
        <div class="nav">
            <a href="#overview">Overview</a>
            <a href="#evidence">Clinical Evidence</a>
            <a href="#methodology">Methodology</a>
            <a href="#scoring">Scoring System</a>
            <a href="#implementation">Implementation</a>
            <a href="#validation">Validation</a>
            <a href="#references">References</a>
        </div>

        <!-- Overview Section -->
        <div class="section" id="overview">
            <h2>üìã What is PRECISE-HBR?</h2>
            
            <h3>Definition</h3>
            <p>The PRECISE-HBR (Predicting bleeding complications in patients undergoing stent implantation and subsequent Dual AntiPlatelet Therapy - High Bleeding Risk) score is a validated clinical decision support tool designed to assess bleeding risk in patients undergoing percutaneous coronary intervention (PCI) who are at high bleeding risk.</p>

            <div class="evidence-box">
                <h3>Key Clinical Impact</h3>
                <p>PRECISE-HBR provides an evidence-based approach to identify high bleeding risk (HBR) patients by:</p>
                <ul>
                    <li><strong>Standardizing HBR Definition:</strong> Uses Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria</li>
                    <li><strong>Predicting 1-Year Bleeding Risk:</strong> Estimates BARC 3-5 bleeding events with validated accuracy</li>
                    <li><strong>Guiding Treatment Decisions:</strong> Helps clinicians optimize antiplatelet therapy duration</li>
                    <li><strong>Improving Patient Outcomes:</strong> Reduces bleeding complications while maintaining ischemic protection</li>
                </ul>
                
                <div class="citation">
                    <strong>Clinical Impact:</strong> Studies show PRECISE-HBR guided therapy can help identify patients who benefit from shorter DAPT duration, reducing bleeding events without increasing ischemic risk.
                </div>
            </div>

            <h3>Target Population</h3>
            <p>PRECISE-HBR is specifically designed for:</p>
            <ul>
                <li>Patients undergoing PCI with stent implantation</li>
                <li>Patients considered for dual antiplatelet therapy (DAPT)</li>
                <li>Patients with potential high bleeding risk factors</li>
                <li>Clinical decision-making regarding DAPT duration</li>
            </ul>
        </div>

        <!-- Clinical Evidence Section -->
        <div class="section" id="evidence">
            <h2>üî¨ Clinical Evidence</h2>
            
            <h3>Development Study</h3>
            <div class="evidence-box">
                <p><strong>Original PRECISE-HBR Study:</strong> Derived and validated using data from multiple international registries and randomized controlled trials, including patients from Europe, Asia, and North America.</p>
                
                <p><strong>Study Population:</strong></p>
                <ul>
                    <li>Over 14,000 patients from derivation cohort</li>
                    <li>External validation in multiple independent cohorts</li>
                    <li>Diverse geographic and demographic representation</li>
                    <li>Follow-up period: 1 year post-PCI</li>
                </ul>
                
                <div class="citation">
                    Primary endpoint: BARC 3-5 bleeding events at 1 year
                </div>
            </div>

            <h3>Validation Studies</h3>
            <p>PRECISE-HBR has been extensively validated across multiple populations:</p>
            <ul>
                <li><strong>C-statistic:</strong> 0.68-0.72 across validation cohorts</li>
                <li><strong>Calibration:</strong> Good agreement between predicted and observed bleeding rates</li>
                <li><strong>Clinical Utility:</strong> Demonstrated improvement in risk stratification compared to clinical judgment alone</li>
                <li><strong>External Validation:</strong> Validated in Asian, European, and North American populations</li>
            </ul>

            <div class="alert alert-info">
                <strong>Performance Metrics:</strong> PRECISE-HBR demonstrates superior discrimination compared to other bleeding risk scores, with consistent performance across different healthcare systems and patient populations.
            </div>
        </div>

        <!-- Methodology Section -->
        <div class="section" id="methodology">
            <h2>‚öôÔ∏è Methodology</h2>
            
            <h3>Score Development Process</h3>
            <ol>
                <li><strong>Variable Selection:</strong> Based on ARC-HBR criteria and clinical expertise</li>
                <li><strong>Statistical Modeling:</strong> Cox proportional hazards regression</li>
                <li><strong>Score Derivation:</strong> Beta coefficients converted to integer scoring system</li>
                <li><strong>Validation:</strong> Bootstrap internal validation and external validation</li>
                <li><strong>Calibration:</strong> Assessed using calibration plots and Hosmer-Lemeshow test</li>
            </ol>

            <h3>ARC-HBR Integration</h3>
            <p>PRECISE-HBR incorporates key elements from the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria:</p>
            <ul>
                <li>Major criteria: ‚â•1 major criterion = HBR</li>
                <li>Minor criteria: ‚â•2 minor criteria = HBR</li>
                <li>Quantitative approach to traditionally qualitative assessments</li>
                <li>Standardized definitions across clinical practice</li>
            </ul>
        </div>

        <!-- Scoring System -->
        <div class="section" id="scoring">
            <h2>üßÆ Scoring System</h2>
            
            <h3>PRECISE-HBR Components</h3>
            <p>The PRECISE-HBR score uses seven readily available clinical parameters:</p>
            
            <table class="score-table">
                <thead>
                    <tr>
                        <th>Parameter</th>
                        <th>Scoring Rules</th>
                        <th>Clinical Rationale</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Age</strong></td>
                        <td>
                            Base score: 2 points<br>
                            If age > 30: (age - 30) √ó 0.25<br>
                            Truncated: 30-80 years
                        </td>
                        <td>Advanced age is a major bleeding risk factor</td>
                    </tr>
                    <tr>
                        <td><strong>Hemoglobin</strong></td>
                        <td>
                            If Hb < 15 g/dL: (15 - Hb) √ó 2.5<br>
                            Truncated: 5-15 g/dL
                        </td>
                        <td>Anemia increases bleeding risk and severity</td>
                    </tr>
                    <tr>
                        <td><strong>eGFR</strong></td>
                        <td>
                            If eGFR < 100: (100 - eGFR) √ó 0.05<br>
                            Truncated: 5-100 mL/min/1.73m¬≤
                        </td>
                        <td>Renal impairment affects drug clearance and bleeding risk</td>
                    </tr>
                    <tr>
                        <td><strong>White Blood Cell Count</strong></td>
                        <td>
                            If WBC > 3.0: (WBC - 3.0) √ó 0.8<br>
                            Truncated: max 15 √ó 10¬≥/ŒºL
                        </td>
                        <td>Elevated WBC may indicate inflammation or systemic illness</td>
                    </tr>
                    <tr>
                        <td><strong>Previous Bleeding</strong></td>
                        <td>
                            No: 0 points<br>
                            Yes: 7 points
                        </td>
                        <td>History of bleeding is the strongest predictor of future bleeding</td>
                    </tr>
                    <tr>
                        <td><strong>Oral Anticoagulation</strong></td>
                        <td>
                            No: 0 points<br>
                            Yes: 5 points
                        </td>
                        <td>Concurrent anticoagulation significantly increases bleeding risk</td>
                    </tr>
                    <tr>
                        <td><strong>ARC-HBR Factors</strong></td>
                        <td>
                            No: 0 points<br>
                            Yes (‚â•1 factor): 3 points
                        </td>
                        <td>Additional high bleeding risk criteria from ARC-HBR consensus</td>
                    </tr>
                </tbody>
            </table>

            <h3>Calculation Formula</h3>
            <div class="code-block">
PRECISE-HBR Score = Base Score (2) + Age Score + Hemoglobin Score + eGFR Score + WBC Score + Previous Bleeding Score + Oral Anticoagulation Score + ARC-HBR Score

Score Range: 2-50+ points
Risk Thresholds: 
- Non-HBR: ‚â§22 points
- HBR: 23-26 points  
- Very HBR: ‚â•27 points

Based on validated V5.0 scoring methodology with truncation limits and rounding to nearest integer for display.
            </div>

            <div class="alert alert-warning">
                <strong>Important:</strong> This implementation uses the official PRECISE-HBR V5.0 scoring methodology with proper truncation limits and base scoring, providing accurate risk assessment consistent with published validation studies.
            </div>

            <h3>Risk Stratification</h3>
            <div class="risk-categories">
                <div class="risk-category low-risk">
                    <h3>Non-HBR</h3>
                    <p><strong>Score: ‚â§22</strong></p>
                    <p><strong>1-Year Bleeding Risk: <4%</strong></p>
                    <p>Standard DAPT duration appropriate</p>
                </div>
                <div class="risk-category moderate-risk">
                    <h3>HBR</h3>
                    <p><strong>Score: 23-26</strong></p>
                    <p><strong>1-Year Bleeding Risk: 4-6%</strong></p>
                    <p>Consider shorter DAPT duration</p>
                </div>
                <div class="risk-category high-risk">
                    <h3>Very HBR</h3>
                    <p><strong>Score: ‚â•27</strong></p>
                    <p><strong>1-Year Bleeding Risk: ‚â•6%</strong></p>
                    <p>Shortest appropriate DAPT duration</p>
                </div>
            </div>
        </div>

        <!-- Implementation Section -->
        <div class="section" id="implementation">
            <h2>üîß Implementation Guide</h2>
            
            <h3>Clinical Workflow Integration</h3>
            <p>PRECISE-HBR can be integrated into clinical practice through:</p>
            <ul>
                <li><strong>EHR Integration:</strong> Automated calculation using existing patient data</li>
                <li><strong>Clinical Decision Support:</strong> Real-time alerts and recommendations</li>
                <li><strong>Point-of-Care Tools:</strong> Bedside calculators and mobile applications</li>
                <li><strong>Quality Metrics:</strong> Population health monitoring and outcomes tracking</li>
            </ul>

            <h3>SMART on FHIR Implementation</h3>
            <p>This implementation provides:</p>
            <ul>
                <li>FHIR R4 compatible data extraction</li>
                <li>Real-time calculation with patient data</li>
                <li>Integration with major EHR systems</li>
                <li>Standardized clinical decision support hooks</li>
            </ul>

            <h3>Data Requirements</h3>
            <table class="score-table">
                <thead>
                    <tr>
                        <th>Parameter</th>
                        <th>FHIR Resource</th>
                        <th>Required/Optional</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Age</td>
                        <td>Patient.birthDate</td>
                        <td>Required</td>
                    </tr>
                    <tr>
                        <td>Hemoglobin</td>
                        <td>Observation (LOINC: 718-7)</td>
                        <td>Required</td>
                    </tr>
                    <tr>
                        <td>eGFR/Creatinine</td>
                        <td>Observation (LOINC: 33914-3, 2160-0)</td>
                        <td>Required</td>
                    </tr>
                    <tr>
                        <td>WBC Count</td>
                        <td>Observation (LOINC: 6690-2)</td>
                        <td>Required</td>
                    </tr>
                    <tr>
                        <td>Previous Bleeding</td>
                        <td>Condition (SNOMED CT)</td>
                        <td>Optional</td>
                    </tr>
                    <tr>
                        <td>Oral Anticoagulation</td>
                        <td>MedicationRequest/MedicationStatement</td>
                        <td>Optional</td>
                    </tr>
                    <tr>
                        <td>ARC-HBR Factors</td>
                        <td>Condition, Observation</td>
                        <td>Optional</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <!-- Validation Section -->
        <div class="section" id="validation">
            <h2>‚úÖ Validation & Performance</h2>
            
            <h3>Statistical Performance</h3>
            <div class="evidence-box">
                <ul>
                    <li><strong>Discrimination (C-statistic):</strong> 0.68-0.72</li>
                    <li><strong>Calibration:</strong> Good across risk deciles</li>
                    <li><strong>Net Reclassification Improvement:</strong> Significant vs. clinical judgment</li>
                    <li><strong>Decision Curve Analysis:</strong> Clinical net benefit demonstrated</li>
                </ul>
            </div>

            <h3>Clinical Validation</h3>
            <ul>
                <li>Validated in multiple international cohorts</li>
                <li>Consistent performance across different populations</li>
                <li>Prospective validation in randomized controlled trials</li>
                <li>Real-world evidence from registry studies</li>
            </ul>

            <h3>Limitations</h3>
            <div class="alert">
                <ul>
                    <li>Requires complete data for optimal performance</li>
                    <li>May need local calibration in some populations</li>
                    <li>Should be used as part of comprehensive clinical assessment</li>
                    <li>Not validated for all bleeding definitions</li>
                </ul>
            </div>
        </div>

        <!-- References Section -->
        <div class="section" id="references">
            <h2>üìö References</h2>
            
            <ol>
                <li><em>Corpataux N, Spirito A, Gragnano F, et al. Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. Eur Heart J. 2020;41(38):3743-3749.</em></li>
                
                <li><em>Cao D, Mehran R, Dangas G, et al. Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. J Am Coll Cardiol. 2020;75(21):2711-2722.</em></li>
                
                <li><em>Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019;40(31):2632-2653.</em></li>
                
                <li><em>Natsuaki M, Morimoto T, Shiomi H, et al. Application of the Academic Research Consortium High Bleeding Risk Criteria in an All-Comers Registry of Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2019;12(11):e008307.</em></li>
                
                <li><em>Ueki Y, B√§r S, Losdat S, et al. Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. EuroIntervention. 2020;16(5):371-379.</em></li>
            </ol>
            
            <div class="evidence-box">
                <p><strong>For the most current clinical guidelines and evidence:</strong></p>
                <ul>
                    <li>European Society of Cardiology (ESC) Guidelines</li>
                    <li>American College of Cardiology/American Heart Association (ACC/AHA) Guidelines</li>
                    <li>Academic Research Consortium for High Bleeding Risk (ARC-HBR) Consensus Documents</li>
                </ul>
            </div>
        </div>

        <!-- Footer -->
        <div class="footer">
            <p>¬© 2024 PRECISE-HBR Bleeding Risk Calculator | Version 5.0 | 
            <a href="/" style="color: #dc3545;">Return to Calculator</a> | 
            <a href="/landing" style="color: #dc3545;">Landing Page</a></p>
            <p style="margin-top: 10px; font-size: 0.8em;">
                This tool is for educational and clinical decision support purposes. Always consult with qualified healthcare professionals for patient care decisions.
            </p>
        </div>
    </div>
</body>
</html> 